Dr. Martens plc (LON:DOCS - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Friday . The stock traded as high as GBX 84 ($1.12) and last traded at GBX 83.86 ($1.12), with a volume of 1542027 shares traded. The stock had previously closed at GBX 82.60 ($1.10).
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on DOCS. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Dr. Martens in a research report on Friday, July 11th. Royal Bank Of Canada reduced their price objective on shares of Dr. Martens from GBX 7,000 ($93.52) to GBX 6,000 ($80.16) and set a "sector perform" rating on the stock in a research note on Monday, May 19th.
Check Out Our Latest Analysis on DOCS
Dr. Martens Trading Down 1.5%
The company has a market capitalization of £782.44 million, a P/E ratio of 11.43, a PEG ratio of 6.40 and a beta of 0.11. The business has a fifty day moving average of GBX 72.59 and a 200-day moving average of GBX 64.50. The company has a debt-to-equity ratio of 127.27, a quick ratio of 1.13 and a current ratio of 2.85.
Dr. Martens (LON:DOCS - Get Free Report) last posted its quarterly earnings data on Thursday, June 5th. The company reported GBX 2.40 ($0.03) earnings per share (EPS) for the quarter. Dr. Martens had a net margin of 7.89% and a return on equity of 18.91%. Analysts anticipate that Dr. Martens plc will post 2.5809394 earnings per share for the current fiscal year.
About Dr. Martens
(
Get Free Report)
Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history.
Read More
Before you consider Dr. Martens, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Martens wasn't on the list.
While Dr. Martens currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.